United States Securities and Exchange Commission · EDGAR Accession 0002048576-26-000002

Form C-AR

Annual Report — Regulation Crowdfunding
Issuer CIK 2048576
Period 2025-12-31

Berkshire Biomedical Corporation

CorporationDEIncorporated 2016Dallas, TXberkshirebiomedical.com
B

Financial Condition

two fiscal years, as filed
Revenue −11% YoYDebt / assets 470%3 employees
Line itemMost recent FYPrior FYΔ
Revenue197,454221,860▼ 11%
Cost of goods sold00
Net income59,066(4,258,282)
Total assets212,889173,383▲ 23%
Cash & equivalents132,063159,350▼ 17%
Accounts receivable00
Short-term debt00
Long-term debt1,000,0000
Taxes paid00

Figures in USD as reported by the issuer.